By Fineline Cube 
Akeso Biopharma (HKG: 9926) announced on June 26, 2026, that Qiyoukang (gumokimab, AK111) has completed its first batch shipment in China following National Medical Products Administration (NMPA) approval for the treatment of adult patients with moderate-to-severe plaque psoriasis. The novel humanized IL-17 monoclonal antibody represents Akeso’s latest commercial launch in the competitive autoimmune disease market.
Regulatory & Commercial Milestones
| Date | Milestone | Indication |
|---|---|---|
| Jun 2026 | NMPA Approval + First Shipment | Moderate-to-severe plaque psoriasis |
| Jun 2026 | NDA Acceptance | Active ankylosing spondylitis (second indication) |
| Development | Independent R&D | Novel humanized IL-17 monoclonal antibody |
Drug Profile & Development Strategy
- Molecule: Gumokimab (AK111, brand name Qiyoukang)
- Target: IL-17 (interleukin-17) pathway
- Class: Novel humanized monoclonal antibody
- Development: Independently developed by Akeso Biopharma with full intellectual property rights
- Therapeutic Area: Autoimmune diseases with initial focus on inflammatory conditions
- Commercial Status: Now available in Chinese market following first batch shipment
Market Opportunity & Competitive Landscape
| Indication | Market Size | Competitive Context |
|---|---|---|
| Plaque Psoriasis | ~6.5 million patients in China | Competes with established IL-17 inhibitors (secukinumab, ixekizumab) and newer biosimilars |
| Ankylosing Spondylitis | ~4-5 million patients in China | Growing market with multiple biologic options; gumokimab would be among newest entrants |
The dual-indication strategy positions gumokimab to capture significant market share across two major autoimmune disease segments, leveraging Akeso’s established commercial infrastructure and physician relationships.
Strategic Implications
- Revenue Diversification: Adds to Akeso’s growing portfolio of commercial-stage assets beyond oncology
- Autoimmune Expansion: Establishes foothold in high-value chronic disease market with recurring treatment patterns
- R&D Validation: Demonstrates Akeso’s capability to successfully develop and commercialize complex biologics independently
- Pipeline Momentum: Second indication under regulatory review provides near-term growth catalyst
- Market Timing: Enters psoriasis market as healthcare system prioritizes chronic disease management and biologic access
The successful first shipment marks a critical transition from development to commercial execution, with gumokimab expected to contribute meaningfully to Akeso’s revenue trajectory in 2026-2027.
Forward-Looking Statements
This brief contains forward-looking statements regarding regulatory approvals, commercial performance, and pipeline development. Actual results may vary based on market adoption, competitive dynamics, and regulatory timelines.-Fineline Info & Tech